Deschloro-N-ethyl-ketamine (DCNEK)
Deschloro-N-ethyl-ketamine (DCNEK) is a novel ketamine analogue research chemical combining the deschloro modification of deschloroketamine with the N-ethyl group of N-ethylnorketamine. It is a dissociative NMDA antagonist with no clinical study and unknown human toxicology.
01 Overview
DCNEK sits structurally between deschloroketamine (DCK) and 2-oxo-PCE/NENK, and appeared on the research-chemical market as another ketamine substitute. Anecdotal reports describe a clear-headed, moderately long dissociative effect, but there is no controlled pharmacology.
No human safety, pharmacokinetic or organ-toxicity data exist. As a ketamine-type dissociative it likely carries the class risks of urinary tract toxicity with heavy use and dependence, and grey-market purity is unverifiable.
02 Mechanism
Non-competitive NMDA receptor antagonist of the ketamine (arylcyclohexanone) class.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Anecdotal (unverified) | 20–60 mg | Insufflated | Anecdotal only; dose-response not established. |
| Anecdotal oral (unverified) | 40–100 mg | Oral | Anecdotal only. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| DissociationKetamine-like detachment and anaesthesia reported at higher doses. | unquantified | Anecdotal | |
| EuphoriaMood lift and stimulation reported at lower doses. | unquantified | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Urinary tract toxicity (presumed)By analogy with ketamine, heavy use may cause ulcerative cystitis. | Severe | Unknown, class risk | Unconfirmed | |
| Dependence potentialKetamine-type dissociatives can drive compulsive binge use. | Moderate | Unknown, class risk | Unconfirmed |